A Boston pharmaceutical executive was charged on one count of securities fraud with earning more than $250,000 by trading on material non-public information, the Justice Department announced Tuesday.
According to the DOJ, in 2022 Dishant Gupta worked as the director of strategy and operations of a global pharmaceutical company and obtained material non-public information about the fact that the company was negotiating to acquire certain assets of a smaller pharmaceutical company based in Boston.
The DOJ said that while in possession of this material non-public information, and in violation of his fiduciary duties to his company, Gupta acquired more ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.